Advertisement

ESMO 2016 Abstract 941TiP - Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study

The randomized, open-label, phase 3 KEYNOTE-183 study (ClinicalTrials.gov, NCT02576977) was designed to compare the efficacy of pomalidomide and low-dose dexamethasone with or without pembrolizumab in patients with rrMM.

 ESMO

click me